Cefepime: Difference between revisions
imported>David E. Volk mNo edit summary |
imported>David E. Volk No edit summary |
||
| Line 7: | Line 7: | ||
|synonyms= | |synonyms= | ||
|molformula= C<sub>19</sub>H<sub>24</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> | |molformula= C<sub>19</sub>H<sub>24</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> | ||
|molmass=480.5611 | |molmass=480.5611 | ||
|uses=antibiotic drug | |uses=antibiotic drug | ||
|properties=beta-lactam | |properties=beta-lactam | ||
| Line 16: | Line 16: | ||
'''Cefepime''' is a fourth-generation [[cephalosporin]] [[antibiotic]] developed in 1994. It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe [[nococomial]] [[pneumonia]], infections of a multi-resistant bacterial strain and the treatment of [[febrile]] [[neutropenia]]. | '''Cefepime''' is a fourth-generation [[cephalosporin]] [[antibiotic]] developed in 1994. It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe [[nococomial]] [[pneumonia]], infections of a multi-resistant bacterial strain and the treatment of [[febrile]] [[neutropenia]]. | ||
== Chemistry == | |||
Cefepime has the IUPAC chemical name (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino] | |||
-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, chemical formula C<sub>19</sub>H<sub>24</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> and molecular mass 480.5611 g/mol. It contains a [[beta-lactam]] moiety that is also present in other cephalosporins and [[penicillin]]s. | |||
== Synonyms and brand names == | |||
Cefepime is also called cefepima in Spanish and cefepimum in Latin. It is sold under the brand names Maxcef®, Cepimax®, Cepimex® and Axepim®. | |||
== External links == | |||
* {{DailyMed}} | |||
* {{MedMaster}} | |||
* {{DrugBank}} | |||
Revision as of 17:54, 24 April 2008
|
| |||||||
| cefepime | |||||||
| |||||||
| Uses: | antibiotic drug | ||||||
| Properties: | beta-lactam | ||||||
| Hazards: | see drug interactions | ||||||
| |||||||
Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. It has more activity than third-generation cephalosporins against Gram-postive and Gram-negative bacteria, and because of this, its use is typically reserved for severe nococomial pneumonia, infections of a multi-resistant bacterial strain and the treatment of febrile neutropenia.
Chemistry
Cefepime has the IUPAC chemical name (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino] -3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, chemical formula C19H24N6O5S2 and molecular mass 480.5611 g/mol. It contains a beta-lactam moiety that is also present in other cephalosporins and penicillins.
Synonyms and brand names
Cefepime is also called cefepima in Spanish and cefepimum in Latin. It is sold under the brand names Maxcef®, Cepimax®, Cepimex® and Axepim®.
External links
- Cefepime - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Template:MedMaster
- Template:DrugBank